Generated by AI
Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing prescription therapies for addiction and related disorders, with a current emphasis on alcohol use disorder. Its lead program, AD04, is a genetically targeted serotonin-3 receptor antagonist being developed to help reduce heavy drinking in patients with specific biomarker profiles. The company also works on additional drug candidates aimed at non-opioid pain reduction and other medical conditions. Adial Pharmaceuticals, Inc. operates as a clinical-stage developer, concentrating on translating research into regulated therapeutic products through clinical studies and product development. The company’s current pipeline reflects a precision-medicine approach that seeks to match treatments with defined patient groups, placing it within the specialized segment of neuroscience and addiction-focused biopharmaceuticals.
Website4870 Sadler Road
Glen Allen, VA, 23060
United States
The latest articles about ADIL.
Summary of Jun 12's posts. Generated by AI.
Summary of Jun 11's posts. Generated by AI.
Former Dermavant Chief Scientific Officer led development of tapinarof, the first FDA-approved AhR agonist, from mechanistic understanding through approval and commercialization Will lead AT177 through IND-enabling studies toward first-in-human trials expected in 2027 GLEN ALLEN, Va., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) ("Adial" or the "Company"), which recently acquired Azora Therapeutics, today announced the appointment of David Rubenstein, M.D., Ph.D.
Summary of Jul 30's posts. Generated by AI.
Investors talking about ADIL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.